GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGCP Infrastructure Investments Regulatory News (GCP)

Share Price Information for GCP Infrastructure Investments (GCP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.90
Bid: 77.90
Ask: 78.10
Change: 0.00 (0.00%)
Spread: 0.20 (0.257%)
Open: 79.80
High: 79.80
Low: 77.70
Prev. Close: 77.90
GCP Live PriceLast checked at -
GCP Infrastructure Investments is an Investment Trust

To provide shareholders with regular, sustainable, long-term dividend income and to preserve the capital value of its investments over the long term by generating exposure to infrastructure debt and/or similar assets.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GCP Applied Technologies Receives European Patent on Sustainable Cement Grinding Methods

18 Oct 2018 11:00



GCP Applied Technologies Receives European Patent on Sustainable Cement Grinding Methods

Bio-derived Solutions Enhance Efficiency of Cement Grinding and Reduce CO2 Emissions

CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- GCP Applied Technologies Inc. (NYSE:GCP), a leading global provider of construction products technologies, is proud to announce the issuance of a patent for increasing the efficiency of cement grinding by using sustainable raw materials. The novel grinding aids and quality improvers allow the use of bio-derived glycerol and reduce the use and the impact of oil-derived chemicals.

This development continues GCP Applied Technologies’ commitment to offer cement producers a complete portfolio of products and services, enabling them to lead in cement quality, cost efficiency and sustainability. The new OPTEVA™ and TAVERO™ cement additives enable cement producers to reduce the energy consumption and the CO2 emissions associated with cement production, with a reduced use, or no use at all, of oil-derived chemicals.

“GCP Applied Technologies is focused on meeting the demands of modern cement plants,” said Dave Myers, vice president R&D and technical support. “We are committed to continuing research and development to improve cement additive products with innovative materials and services. GCP offers cement producers a complete portfolio of solutions that yield more sustainable cement production with enhanced quality and improved cost efficiency.”

European Patent No. EP 1 728 771 B1 has been granted and registered into seventeen European countries. The patent addresses methods for increasing the efficiency of cement and mineral grinding by using sustainable raw materials.

The patent relates to methods for improving the efficiency of grinding materials such as clinker and limestone, using glycerol derived from biofuel production, in combination with various grinding additives. GCP products can help shrink the carbon footprint of cement and concrete. Grinding aids and quality improvers make cement manufacturing more efficient, while concrete admixtures can reduce the amount of cement needed to achieve a given strength specification.

The company continues to expand its comprehensive portfolio of additives for cement production with high-performing quality improvers under the OPTEVA™ brand and innovative grinding aids under the TAVERO™ brand. 

Media RelationsPaul KeeffeT +1 617.498.4461mediainfo@gcpat.comInvestor RelationsJoseph DeCristofaroT +1 617.498.2616investors@gcpat.com

About GCP Applied Technologies

GCP is a leading global provider of construction products technologies that include additives for cement and concrete, the VERIFI® in-transit concrete management system, high-performance waterproofing products, and specialty systems. GCP products have been used to build some of the world’s most renowned structures. More information is available at www.gcpat.com.

This announcement contains “forward-looking statements,” that is, information related to future, not past, events. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. Forward-looking statements include, without limitation, statements about expected financial positions; results of operations; cash flows; financing plans; business strategy; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; and markets for securities. Like other businesses, GCP is subject to risks and uncertainties that could cause its actual results to differ materially from its projections or that could cause other forward-looking statements to prove incorrect. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, risks related to: the cyclical and seasonal nature of the industries that GCP serves; foreign operations, especially in emerging regions; changes in currency exchange rates; the cost and availability of raw materials and energy; the effectiveness of GCP’s research and development, new product introductions and growth investments; acquisitions and divestitures of assets and gains and losses from dispositions; developments affecting GCP’s outstanding liquidity and indebtedness, including debt covenants and interest rate exposure; developments affecting GCP’s funded and unfunded pension obligations; warranty and product liability claims; legal proceedings; the inability to establish or maintain certain business relationships and relationships with customers and suppliers or the inability to retain key personnel; and the handling of hazardous materials and the costs of compliance with environmental regulation. These and other factors are identified and described in more detail in GCP's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available online at www.sec.gov. Readers are cautioned not to place undue reliance on GCP’s projections and forward-looking statements, which speak only as the date thereof. GCP undertakes no obligation to publicly release any revision to the projections and forward-looking statements contained in this announcement, or to update them to reflect events or circumstances occurring after the date of this announcement.


Date   Source Headline
10th Jul 20177:00 amRNSPlacing under Placing Programme
6th Jun 20173:31 pmRNSDirector/PDMR Shareholding
2nd Jun 201711:18 amRNSDirector/PDMR Shareholding
2nd Jun 201711:18 amRNSTotal Voting Rights
25th May 20177:00 amRNSHalf-yearly report and financial statements 2017
24th May 201710:51 amRNSAdditional Listing
8th May 20174:52 pmRNSSCRIP Dividend Circular
2nd May 201710:22 amRNSInvestor Report - 31 March 2017
2nd May 20179:26 amRNSInvestor Report - 31 March 2017
26th Apr 20172:35 pmRNSAdditional investment commitment of up to £40.0m
20th Apr 201712:57 pmRNSDividend Declaration & Scrip Dividend Alternative
20th Apr 201710:18 amRNSConditional investment commitment
20th Apr 20178:11 amRNSNovation of investment advisory agreement
10th Apr 20173:52 pmRNSNet Asset Value(s)
28th Mar 20174:21 pmRNSPublication of a Prospectus
8th Mar 20172:39 pmRNSDirector/PDMR Shareholding
3rd Mar 201710:26 amRNSDirector/PDMR Shareholding
3rd Mar 201710:24 amRNSTotal Voting Rights
21st Feb 201710:45 amRNSAdditional Listing
13th Feb 20174:58 pmRNSReplacement: Result of AGM
10th Feb 20173:57 pmRNSResult of EGM
10th Feb 20173:54 pmRNSResult of AGM
3rd Feb 20174:56 pmRNSSCRIP Dividend Circular
30th Jan 20171:26 pmRNSInvestor Report - 31 December 2016
18th Jan 20173:44 pmRNSRevolving Credit Facility
17th Jan 20175:31 pmRNSNew Directorship Notification
17th Jan 20172:11 pmRNSDividend Declaration
10th Jan 20177:00 amRNSNet Asset Value(s)
5th Jan 20174:59 pmRNSNotice of AGM & EGM
14th Dec 20163:03 pmRNSNotification of Major Interest in Shares
14th Dec 201611:38 amRNSReplacement Annual Financial Report
14th Dec 20167:15 amRNSPublication of Supplementary Prospectus
14th Dec 20167:00 amRNSAnnual Report and Financial Statements
9th Dec 20164:53 pmRNSDirector/PDMR Shareholding
1st Dec 20169:47 amRNSTotal Voting Rights
29th Nov 20163:29 pmRNSNotification of Major Interest in Shares
29th Nov 20169:56 amRNSResult of Placing and Additional Listing
18th Nov 20167:00 amRNSPlacing under the Placing Programme
15th Nov 20163:08 pmRNSAdditional Listing and Total Voting Rights
1st Nov 20167:00 amRNSScrip Dividend Circular
14th Oct 20161:19 pmRNSReplacement Dividend Declaration & Scrip Dividend
14th Oct 20169:27 amRNSDividend Declaration
13th Oct 20164:13 pmRNSInvestor Report - 30 September 2016
10th Oct 20167:00 amRNSInvestment commitment of up to c.£60.0 million
7th Oct 20165:24 pmRNSNet Asset Value(s)
30th Aug 201610:55 amRNSTotal Voting Rights
17th Aug 20165:19 pmRNSAdditional Listing
1st Aug 20165:00 pmRNSScrip Dividend Circular
29th Jul 201612:00 pmRNSTotal Voting Rights
26th Jul 20164:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.